Neoadjuvant Rectal Score And Downstaging Depth Score As Prognosis Predictors For Patients With Locally Advanced Rectal Cancer

Chen, S.; Tang, Yu; Li, N.; Liu, W.; Jiang, Jeng-Kae; Jiang, Long; Chen, B.; Fang, Hui; Ren, hongjian; Liu, Ningning; Wang, S.; Song, Yujae; Liu, Y.; Li, Y.; Jin, Jian-Yue

doi:10.1016/j.ijrobp.2020.07.1896

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a comprehensive review by Glynne–Jones, the authors meticulously assessed the NAR score and its association with survival. Of 58 total publications, 14 studies reported 5‐year OS rates, with the low NAR subgroup ranging between 80% and 100%, 71% and 89% within the intermediate NAR subgroup, and 47% and 68% within the high NAR subgroup 15,17–30 . This NCDB cohort demonstrated similar 5‐year OS outcomes for low, intermediate, and high NAR scores, respectively, within the matched group not receiving AC (85% vs. 76% vs. 68%) as well as the matched group receiving AC (93% vs. 88% vs. 75%, low, intermediate, high NAR score, respectively (Figures 2 and 3).…”

Section: Discussionmentioning

confidence: 86%

Neoadjuvant rectal score is prognostic for survival: A population‐based propensity‐matched analysis

Naffouje

Manguso

Imanirad

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

Introduction: Neoadjuvant rectal (NAR) score may serve as a surrogate short-term endpoint for overall survival (OS) in clinical trials. This study aims to test the NAR score using a large, national cancer registry.Methods: National Cancer Database patients with clinical stage II/III rectal adenocarcinoma (RAC) treated with neoadjuvant chemoradiation (CRT) followed by surgery were selected and divided into low-, intermediate-, and high-NAR subgroups. OS outcomes were analyzed using Kaplan-Meier and logistic regression models.Results: A total of 12 452 patients were selected, of which 5071 (40.7%) were in clinical stage II and 7381 (59.3%) were in clinical stage III; 15.2% had pathologic complete response. The mean NAR score was 10.01 ± 10.61. Six thousand nine hundred and forty-one (55.7%) did not receive adjuvant chemotherapy (AC) and were propensity-matched across NAR subgroups (966 in each group). A significant difference in 5-year OS between low-, intermediate-, and high-NAR groups was observed (85% vs. 76% vs. 68%; p < 0.001). Five thousand five hundred and eleven (44.3%) received AC and 1045 triplets were propensity-matched per NAR groups. A significant difference was again observed for 5-year OS (93% vs. 88% vs. 75%; p < 0.001). Logistic regression confirmed NAR strata as a significant predictor of 5-year OS.Conclusion: NAR score, as a neoadjuvant response measure, is a strong predictor of 5-year OS, regardless of AC receipt in a heterogenous population of locally advanced RAC patients.

show abstract

Section: Discussionmentioning

confidence: 86%

Neoadjuvant rectal score is prognostic for survival: A population‐based propensity‐matched analysis

Naffouje

Manguso

Imanirad

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…As a secondary objective, we evaluated the days of treatment interruption and their influence on tumor and nodal downstaging after neoadjuvant therapy, knowing that downstaging has been proposed as a predictive factor for the outcome of patients with rectal cancer [ 21 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact on Survival of Neoadjuvant Treatment Interruptions in Locally Advanced Rectal Cancer Patients

Lișcu,

Antone-Iordache,

Atasiei

et al. 2024

JPM

View full text Add to dashboard Cite

The standard oncologic treatment of locally advanced rectal cancer is long-course radio-chemotherapy followed by surgery and adjuvant chemotherapy. This can result in a lengthy total treatment duration, sometimes up to one year from the diagnosis. Interruptions to neoadjuvant treatment can occur for a variety of reasons, forced or unforced. The main purpose of this study is to analyze the survival data of locally advanced rectal cancer patients who received neoadjuvant treatment and to find a cut-off point showing exactly how many days of interruption of neoadjuvant treatment the risk of death or disease relapse increases. We conducted a retrospective study on 299 patients with locally advanced rectal cancer using survival analysis (Kaplan–Meier curve and Cox regression) to determine survival probabilities for overall survival, local control, and disease-free survival. Patients with 0 to 3 days of neoadjuvant therapy interruption had a higher overall survival probability compared to patients with 4 or more days (90.2% compared to 57.9%, p-value < 0.001), hazard ratio 5.89 (p < 0.001). Local control and disease-free survival had a higher probability in patients with 0–2 days of interruption compared to people with 3 or more days (94% vs. 75.4%, and 82.2% vs. 50.5%, respectively, both p-values < 0.001). Patients with tumoral or nodal downstaging experienced fewer days of interruption than patients with no downstage. These findings reinforce the need for radiation oncologists to be well-organized when starting neoadjuvant treatment for rectal cancer, in order to anticipate and prevent potential treatment interruptions and achieve the best therapeutic results.

show abstract

The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer

Glynne‐Jones

Glynne-Jones

2021

The Lancet Oncology

View full text Add to dashboard Cite

Neoadjuvant Rectal Score And Downstaging Depth Score As Prognosis Predictors For Patients With Locally Advanced Rectal Cancer

Cited by 3 publications

References 0 publications

Neoadjuvant rectal score is prognostic for survival: A population‐based propensity‐matched analysis

Neoadjuvant rectal score is prognostic for survival: A population‐based propensity‐matched analysis

The Impact on Survival of Neoadjuvant Treatment Interruptions in Locally Advanced Rectal Cancer Patients

The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer

Contact Info

Product

Resources

About